Tampax Lead Lawsuit Class Certification: Judge Certifies California Buyers' Class Against P&G

A federal judge in San Diego certified a class of California consumers on Tuesday, September 29, 2026, in the Tampax lead lawsuit against Procter & Gamble, allowing buyers of Tampax Pearl and Tampax Radiant tampons to pursue as a group the claim that P&G concealed the presence of lead in those products. The Tampax lead lawsuit class certification, entered by Judge Gonzalo P. Curiel in Barton v. The Procter & Gamble Co., No. 3:24-cv-01332, converts a two-year pleading fight into a certified economic-loss case with real settlement pressure, even though the FDA said in July 2026 that metals released from tampons are too small to cause harm.

The order was reported on September 30 by Law360, whose headline describes the class as California buyers. The full text of the order, including the precise class definition, the class period, and which of the pleaded California statutory claims the court certified, was not available in any source this desk could access at publication. This article sets out what is confirmed, what the certification means under Rule 23, how the case reached this point, and what comes next for P&G, class members, and the plaintiffs' bar watching a growing docket of heavy-metal consumer cases.

What happened in the Tampax lead lawsuit?

The case began in July 2024, when Allison Barton filed a proposed Class Action in the Southern District of California alleging that P&G sold Tampax Pearl tampons that contained lead without telling consumers. Jana Moreno later joined as a second Named Plaintiff, and the case expanded to cover Tampax Radiant. The core theory is an omission: plaintiffs say lead content is a fact a reasonable consumer would want to know before buying a product worn internally, and that P&G's packaging and marketing presented Tampax as safe while saying nothing about lead.

On September 29, 2026, Judge Curiel granted Class Certification for a class of California purchasers. The plaintiffs are represented as a class going forward; unless the certification is reversed or narrowed, class members will be bound by the outcome of the case, whether a trial verdict or a court-approved settlement, unless they opt out after Class Notice.

The certification is the most significant ruling in the Tampax lead litigation to date. Earlier rulings in the same case addressed only whether the complaint stated a claim. Certification is the first ruling that addresses whether the claims can be tried on common, classwide proof, and it is the point in consumer litigation at which exposure moves from theoretical to aggregate.

Key facts at a glance:

• Court: U.S. District Court for the Southern District of California
• Judge: Gonzalo P. Curiel (Magistrate Judge Steve B. Chu handles referred matters)
• Case: Barton v. The Procter & Gamble Co., No. 3:24-cv-01332-GPC-SBC
• Plaintiffs: Allison Barton and Jana Moreno
• Products: Tampax Pearl and Tampax Radiant
• Ruling: class of California consumers certified, September 29, 2026
• Relief sought: economic damages (refund or price differential) and injunctive relief (labeling)

Who is included in the certified Tampax class?

The certified class is made up of California consumers who bought the Tampax products at issue, according to Law360's report of the September 29 order. The order's exact wording, including the class period and whether both Pearl and Radiant purchasers or particular absorbencies are covered, had not been published in any accessible source by September 30, 2026. Anyone trying to determine membership should rely on the Class Notice the court will later approve, not on secondary summaries.

Three points about scope are already clear from the case record.

First, this is a California class. The case pleads California consumer-protection statutes, and the separate federal cases filed elsewhere against P&G seek to represent purchasers in other states. One of them, Otkina v. Procter & Gamble, filed in the Northern District of Illinois on January 28, 2026, expressly seeks a nationwide class excluding California residents, which signals that plaintiffs' counsel in the different cases have divided the country rather than competing for the same buyers.

Second, the class is defined by purchase, not by injury. A person does not need to show a medical condition, elevated blood lead, or any physical harm to be a class member. That is a structural difference from a personal-injury Mass Tort, where each claimant must prove Specific Causation.

Third, ordinary Rule 23 mechanics apply. Because the plaintiffs sought damages, the class will almost certainly proceed as a Rule 23(b)(3) Opt-Out Class, meaning members receive notice and may exclude themselves. Ascertainability in the Ninth Circuit does not require proof that each buyer can be identified from records at certification, which matters for a product sold at retail with few receipts kept.

Is there a Tampax lead settlement or claim form?

No. As of September 30, 2026, there is no Tampax lead settlement, no settlement fund, and no claim form in Barton or any related case. The certification order is not a finding that P&G did anything wrong and does not award money to anyone. Websites that invite readers to "file a Tampax claim" are, at most, law-firm intake pages for individual representation; they are not claims processes.

The parties have explored resolution before. In September 2025, the magistrate judge ordered early neutral evaluation and settlement discussions. No agreement followed. Certification often changes the calculus: a certified class gives the plaintiffs a single, aggregated damages claim and gives the defendant a single set of claims it can resolve with finality through a court-approved settlement.

If a settlement is reached, it would follow the familiar class sequence: a motion for preliminary approval, Class Notice to members, a claims period, objections, a fairness hearing, and final approval. None of those steps has begun.

How the Tampax lead case reached certification: timeline

The case took more than two years and several contested rulings to reach certification. The table below sets out the dated milestones confirmed in court records and reporting.

Date	Event
June–July 2024	UC Berkeley-led study in Environment International reports measurable metals, including lead, in all 30 tampons tested from 14 brands
July 2024	Allison Barton files proposed class action against P&G in the Southern District of California
September 2024	FDA announces it will study metals in tampons, commissioning a literature review and a laboratory study
Late December 2024	FDA publishes a literature review of nine studies, finding no safety concerns tied to tampon use and contaminant exposure
February 13, 2025	Judge Curiel grants in part and denies in part P&G's motion to dismiss; gives 25 days to amend
2025	Court rejects P&G's primary jurisdiction argument (Barton, 766 F. Supp. 3d 1045)
2025	Court dismisses UCL "unfair" prong claims in the tampon lead cases with prejudice, while largely denying dismissal
September 2025	Magistrate judge orders early neutral evaluation and settlement talks
November 19, 2025	Sanchez v. Procter & Gamble, No. 1:25-cv-00852, filed on behalf of plaintiffs from nine states
December 11, 2025	Court denies P&G's motion to transfer Barton to Ohio
January 28, 2026	Otkina v. Procter & Gamble filed in the Northern District of Illinois, seeking a nationwide class excluding California
July 6, 2026	FDA announces laboratory study results: trace metals present, release too small to cause harm
September 29, 2026	Judge Curiel certifies class of California buyers

What the pleading-stage rulings decided

The certification makes more sense read against the earlier rulings, which shaped the claims that survived to the class stage.

Testing had to cover what was sold. In the February 13, 2025 order, Judge Curiel accepted the plaintiffs' allegations that independent laboratory testing detected 0.181 micrograms of lead per gram of Tampax Pearl and 0.123 micrograms per gram of Tampax Radiant. But he dismissed claims over product sizes the plaintiffs had purchased but not tested, directing them either to test those products or to explain why the results for the tested absorbencies could fairly be extrapolated. The dismissal was without prejudice, with 25 days to file an amended complaint. Bloomberg Law described the result as P&G trimming the suit; the core of the case survived.

The FDA did not get first say. P&G asked the court to pause the case under the primary jurisdiction doctrine, which lets a court defer to an agency with regulatory expertise over an issue. The argument had surface appeal: the FDA had announced its own study of metals in tampons. The court refused. Commentator Rebecca Tushnet summarized the ruling, reported at 766 F. Supp. 3d 1045, as a primary jurisdiction argument that went down "like a lead balloon," and noted the court allowed the usual California claims to proceed, including for injunctive relief.

The "unfair" prong fell away. In a later 2025 ruling covering the tampon lead suits, the court largely denied further motions to dismiss but dismissed with prejudice claims under the "unfair" prong of California's Unfair Competition Law (UCL), according to Mealey's. That left the fraud-based and unlawful-conduct theories, and the California Consumers Legal Remedies Act (CLRA) and False Advertising Law (FAL) claims, as the main vehicles.

The case stayed in California. P&G, headquartered in Cincinnati, moved to transfer the case to Ohio, where other Tampax lead litigation was pending. On December 11, 2025, the court denied the motion, keeping a California consumer class in a California court under California law.

What does class certification mean for P&G?

Class certification means P&G now faces a single, aggregated claim on behalf of every California buyer within the class definition, rather than two individual plaintiffs whose own damages would be the cost of a few boxes of tampons. For consumer claims, that is the difference between a Negative-Value Claim nobody would litigate alone and a case measured against total California sales over the class period.

To certify a damages class under Rule 23(b)(3), the court had to find the four Rule 23(a) requirements (Numerosity, Commonality, Typicality, and Adequacy of Representation) and then that common questions predominate over individual ones and that a class action is superior to other methods. In a consumer omission case, three questions usually decide Predominance.

Materiality and reliance. California law allows classwide proof of reliance where the omitted fact is material to a reasonable consumer. Under the California Supreme Court's decision in In re Tobacco II Cases (2009), absent class members in a UCL action need not each prove individual reliance, and the CLRA permits an inference of reliance classwide when the omission is material. Whether lead content is material to a reasonable tampon buyer is an objective, common question, answerable once for everyone.

Uniform exposure. The omission theory works best when every buyer saw the same packaging and none was told about lead. Unlike an affirmative-misrepresentation case built on a particular advertisement, an omission case does not usually require proof that each class member saw a specific statement.

A classwide damages model. Under Comcast Corp. v. Behrend (2013), the plaintiffs must offer a damages model that measures only the harm attributable to their theory of liability. In food and consumer-product cases, courts in the Ninth Circuit commonly accept price-premium models, often built on conjoint surveys, that estimate how much less buyers would have paid had the omitted fact been disclosed. The accessible reporting does not say which model the court accepted here. In Olean Wholesale Grocery Cooperative v. Bumble Bee Foods (9th Cir. 2022) (en banc), the Ninth Circuit held that plaintiffs must prove Rule 23 prerequisites by a preponderance of the evidence, but rejected a rule barring certification whenever some class members may be uninjured.

The practical consequence for P&G is leverage. Certified consumer classes settle far more often than they go to verdict, because the aggregate exposure, the cost of notice and trial, and the reputational stakes of a jury trial about lead in a feminine-care product all arrive at once.

Did the FDA find lead in tampons is dangerous?

No. The FDA's laboratory study, announced July 6, 2026 and published in Toxicological Sciences, confirmed that lead, arsenic, and cadmium are present at trace levels in tampons but concluded that the amounts released during use are not expected to cause adverse health effects. The agency tested 11 tampon products legally marketed in the United States using inductively coupled plasma mass spectrometry and detected 19 metals.

The study was built to overstate exposure. The FDA measured release under what it called exaggerated conditions, soaking products at 50°C for 24 hours in acidified water, and still found leaching negligible. It reported margins of safety of 7 or greater, which the agency treats as a low toxicological concern. That followed a literature review the FDA published in late December 2024, prepared by International Consulting Associates, which surveyed nine studies on contaminants in tampons and found no safety concerns.

The FDA's work responded to the 2024 study led by UC Berkeley researchers and published in Environment International, which tested 30 tampons from 14 brands for 16 metals and metalloids. That study found lead in every tampon tested, found higher lead in non-organic tampons and higher arsenic in organic ones, and reported higher lead in products sold in the United States than in Europe. It measured metal content, not how much crosses into the body, a gap the Berkeley authors themselves flagged and the FDA set out to address.

Why the FDA study did not stop certification

It is tempting to read the FDA's July 2026 finding as fatal to the case. At the class-certification stage it was not, for two reasons rooted in how the claims are framed.

First, the case is about disclosure and price, not injury. Plaintiffs do not have to prove that Tampax caused lead poisoning. They have to prove that lead content is material to a reasonable consumer and that buyers paid more than they would have if it had been disclosed. A product can be safe under a toxicological risk assessment and still carry a fact that many buyers would want to know. That tension is the merits dispute the class will now litigate.

Second, certification asks whether questions can be answered on common proof, not how they will be answered. Whether the FDA's findings defeat materiality is itself a common question. If a jury accepts P&G's position that trace lead within FDA-acceptable margins is not material, the class loses together. That is a reason certification can coexist with a strong merits defense.

The FDA study will matter at summary judgment and trial. It gives P&G a federal regulator's conclusion that release is negligible, supports an argument that reasonable consumers would not be misled, and could shape how a jury values any price premium. Defense commentators at the Drug & Device Law blog argued in August 2026 that the study also warrants revisiting preemption. Tampons are Class II medical devices cleared through the FDA's 510(k) process under 21 C.F.R. § 884.5470, and 21 C.F.R. § 801.430 prescribes specific labeling on toxic shock syndrome. Under Medtronic v. Lohr (1996), 510(k)-cleared devices generally do not receive express Preemption (Products), so any preemption argument would be implied and would face the court's earlier refusal to defer to the FDA.

Can P&G appeal the class certification ruling?

Yes, but only with permission. Under Federal Rule of Civil Procedure 23(f), P&G may petition the U.S. Court of Appeals for the Ninth Circuit for permission to appeal the certification order within 14 days after it is entered, which for a September 29 order runs to October 13, 2026. The Ninth Circuit grants such petitions sparingly, generally where the order presents an unsettled and fundamental issue of class-action law, where it is manifestly erroneous, or where it creates a "death knell" situation for either side.

A Rule 23(f) petition does not automatically stay proceedings in the district court. P&G may also ask Judge Curiel to reconsider or to decertify later if the evidence develops differently, because a certification order can be altered or amended before final judgment under Rule 23(c)(1)(C).

Are there other Tampax lead lawsuits outside California?

Yes. P&G faces at least two other federal proposed class actions over lead in Tampax products, and Kimberly-Clark faces a parallel suit over U by Kotex tampons before the same judge. None of these has been reported as certified, and the Tampax cases have not been centralized in a Multidistrict Litigation (MDL).

Case	Court	Filed	Proposed class	Status (Sept. 30, 2026)
Barton v. Procter & Gamble, No. 3:24-cv-01332	S.D. Cal. (Curiel, J.)	July 2024	California purchasers	Class certified Sept. 29, 2026
Sanchez v. Procter & Gamble, No. 1:25-cv-00852	Federal court	Nov. 19, 2025	Purchasers in nine states	Early pleading stage
Otkina v. Procter & Gamble	N.D. Ill.	Jan. 28, 2026	Nationwide, excluding California	Early pleading stage
U by Kotex lead suit against Kimberly-Clark	S.D. Cal. (Curiel, J.)	2024	Consumer purchasers	Survived dismissal in part; fraud claims dismissed with leave to amend earlier in the case

The Kotex case tracks Barton closely. Judge Curiel initially dismissed its fraud claims without prejudice because the plaintiff had not described the independent testing in enough detail, but allowed consumer-protection claims to proceed to the extent they alleged that Kimberly-Clark's representations led reasonable consumers to believe the products were lead-free. Bloomberg Law later reported that the Kotex maker could not shake the suit. With the same judge now having certified a class against P&G, the Kotex plaintiffs have a road map, and Kimberly-Clark has an early view of how the court applies Rule 23 to the same theory.

What damages can Tampax class members recover?

Class members in Barton can recover, at most, economic damages and injunctive relief, not personal-injury compensation. The pleaded remedies are restitution or damages measured as a full or partial refund or a price differential, and an injunction requiring labeling changes. Because the claims rest on purchase rather than injury, any recovery per person is likely to be modest, tied to the number of boxes bought and the price premium a court or jury accepts.

Anyone who believes they suffered a physical injury from lead exposure would need to bring an individual personal-injury claim, subject to the applicable Statute of Limitations, and would need medical and scientific proof of causation. No personal-injury Mass Tort over tampon metals has been organized, and the FDA's July 2026 findings make General Causation a steep climb for any such claim.

What it means for the practice

For consumer-product defendants. Barton shows that a federal regulator's "no health concern" finding does not end an omission case at certification. Defendants facing contaminant claims (heavy metals in baby food, PFAS in apparel, benzene in aerosols) should expect plaintiffs to frame materiality as a common question and to present a price-premium model early. Pleading-stage wins on product testing, like the February 2025 ruling here, narrow a case but rarely end it; plaintiffs can re-test and replead.

For defense counsel on regulatory strategy. Primary jurisdiction lost here even while the FDA was actively studying the question. The better use of the agency's findings is on the merits, through materiality and damages experts who can explain margins of safety to a jury, and through any available preemption argument after the FDA's 2026 work.

For plaintiffs' firms. The division of the market (California in Barton, other states in Sanchez, a nationwide-minus-California class in Otkina) avoids first-to-file fights and lets a certified California class set a benchmark. Firms with heavy-metal consumer dockets should note what carried certification: product-specific testing, an objective materiality theory, and a damages model that fits the omission. Economic-loss classes are paid through class fees rather than a Contingency Fee on individual injury claims, and the Common Fund Doctrine will govern any fee award from a settlement.

For litigation funders. Certified consumer classes with national brands are attractive for Third-Party Litigation Funding because certification removes a major risk. The regulatory overhang cuts the other way: the FDA study raises merits risk at trial and may depress settlement value.

For personal injury lawyers fielding inquiries. Clients asking about "the Tampax lawsuit" should be told plainly that the certified case is about refunds and labeling, that there is no settlement or claim form, and that individual injury claims face the FDA's July 2026 findings.

Frequently asked questions

What did the judge decide in the Tampax lead lawsuit?

On September 29, 2026, Judge Gonzalo P. Curiel of the Southern District of California certified a class of California consumers in Barton v. The Procter & Gamble Co., allowing buyers of Tampax Pearl and Radiant tampons to pursue as a group the claim that P&G failed to disclose lead in the products.

Does class certification mean P&G is liable?

No. Certification decides only that the claims can be litigated on classwide proof. P&G has not been found liable, and it can still defeat the claims at summary judgment or trial, including by relying on the FDA's July 2026 finding that metal release from tampons is negligible.

Do I need to sign up to be part of the Tampax class?

Not if you fall within the class definition. In a Rule 23(b)(3) class, members are included automatically unless they opt out after receiving court-approved Class Notice, which has not yet been issued.

How much lead was found in Tampax tampons?

The plaintiffs' independent testing, as pleaded, found 0.181 micrograms of lead per gram in Tampax Pearl and 0.123 micrograms per gram in Tampax Radiant. The FDA's separate 2026 study found lead and other metals at trace levels but concluded the amounts released during use are too small to cause harm.

Is there a Tampax settlement payout?

No. There is no settlement, no settlement fund, and no claim form in any Tampax lead case as of September 30, 2026.

What happens next in the Tampax case?

P&G has until October 13, 2026 to petition the Ninth Circuit for permission to appeal under Rule 23(f). If no appeal is allowed, the case moves toward class notice, expert challenges over materiality and the damages model, summary judgment, and either settlement or trial.